ADXN
Price
$3.11
Change
+$0.08 (+2.64%)
Updated
Oct 22 closing price
Capitalization
3.94M
42 days until earnings call
Intraday BUY SELL Signals
PHAT
Price
$7.01
Change
-$0.02 (-0.28%)
Updated
Oct 22 closing price
Capitalization
567.12M
7 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ADXN vs PHAT

ADXN vs PHAT Comparison Chart in %
View a ticker or compare two or three
VS
ADXN vs. PHAT commentary
Oct 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ADXN is a Hold and PHAT is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for ADXN with price predictions
Oct 22, 2026

ADXN in -2.31% downward trend, declining for three consecutive days on October 19, 2026

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where ADXN declined for three days, in 226 of 249 cases, the price declined further within the following month. The odds of a continued downward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Aroon Indicator for ADXN entered a downward trend on October 07, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ADXN's RSI Indicator exited the oversold zone, 20 of 23 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 67 of 78 cases where ADXN's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.

The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on ADXN as a result. In 102 of 133 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 77%.

Following a +3.30% 3-day Advance, the price is estimated to grow further. Considering data from situations where ADXN advanced for three days, in 158 of 200 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.

ADXN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 70 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.063) is normal, around the industry mean (2.973). P/E Ratio (-0.432) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (86.207) is also within normal values, averaging (438.009).

The Tickeron Price Growth Rating for this company is 88 (best 1 - 100 worst), indicating slightly worse than average price growth. ADXN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ADXN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for PHAT with price predictions
Oct 22, 2026

PHAT's RSI Indicator ascending out of oversold territory

The RSI Oscillator for PHAT moved out of oversold territory on October 07, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 29 similar instances when the indicator left oversold territory. In 27 of the 29 cases the stock moved higher. This puts the odds of a move higher at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 57 of 62 cases where PHAT's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.

The Moving Average Convergence Divergence (MACD) for PHAT just turned positive on October 08, 2026. Looking at past instances where PHAT's MACD turned positive, the stock continued to rise in 40 of 47 cases over the following month. The odds of a continued upward trend are 85%.

Following a +5.64% 3-day Advance, the price is estimated to grow further. Considering data from situations where PHAT advanced for three days, in 242 of 287 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 22, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PHAT as a result. In 62 of 72 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PHAT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.

The Aroon Indicator for PHAT entered a downward trend on October 15, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 17 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-1.647) is normal, around the industry mean (2.973). P/E Ratio (-5.608) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (2.511) is also within normal values, averaging (438.009).

The Tickeron Price Growth Rating for this company is 82 (best 1 - 100 worst), indicating slightly worse than average price growth. PHAT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PHAT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
ADXN vs PHAT: Fundamental Ratings
ADXN
PHAT
OUTLOOK RATING
1..100
6428
VALUATION
overvalued / fair valued / undervalued
1..100
70
Overvalued
17
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
99100
PRICE GROWTH RATING
1..100
8882
P/E GROWTH RATING
1..100
1014
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PHAT's Valuation (17) in the null industry is somewhat better than the same rating for ADXN (70). This means that PHAT’s stock grew somewhat faster than ADXN’s over the last 12 months.

PHAT's Profit vs Risk Rating (100) in the null industry is in the same range as ADXN (100). This means that PHAT’s stock grew similarly to ADXN’s over the last 12 months.

ADXN's SMR Rating (99) in the null industry is in the same range as PHAT (100). This means that ADXN’s stock grew similarly to PHAT’s over the last 12 months.

PHAT's Price Growth Rating (82) in the null industry is in the same range as ADXN (88). This means that PHAT’s stock grew similarly to ADXN’s over the last 12 months.

ADXN's P/E Growth Rating (10) in the null industry is in the same range as PHAT (14). This means that ADXN’s stock grew similarly to PHAT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ADXNPHAT
RSI
ODDS (%)
Bullish Trend 1 day ago
87%
Bullish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
86%
Bullish Trend 1 day ago
90%
Momentum
ODDS (%)
Bullish Trend 1 day ago
77%
Bearish Trend 1 day ago
86%
MACD
ODDS (%)
N/A
Bullish Trend 1 day ago
85%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
79%
Bearish Trend 1 day ago
85%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
85%
Advances
ODDS (%)
Bullish Trend 9 days ago
79%
Bullish Trend 3 days ago
84%
Declines
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 1 day ago
87%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
90%
N/A
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
87%
COMPARISON
Comparison
Oct 23, 2026
Stock price -- (ADXN: $3.03 vs. PHAT: $7.03)
Brand notoriety: ADXN and PHAT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ADXN: 2% vs. PHAT: 55%
Market capitalization -- ADXN: $3.94M vs. PHAT: $567.12M
ADXN [@Biotechnology] is valued at $3.94M. PHAT’s [@Biotechnology] market capitalization is $567.12M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $135.64B. The average market capitalization across the [@Biotechnology] industry is $2.18B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ADXN’s FA Score shows that 1 FA rating(s) are green while PHAT’s FA Score has 2 green FA rating(s).

  • ADXN’s FA Score: 1 green, 4 red.
  • PHAT’s FA Score: 2 green, 3 red.
According to our system of comparison, PHAT is a better buy in the long-term than ADXN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ADXN’s TA Score shows that 5 TA indicator(s) are bullish while PHAT’s TA Score has 6 bullish TA indicator(s).

  • ADXN’s TA Score: 5 bullish, 3 bearish.
  • PHAT’s TA Score: 6 bullish, 2 bearish.
According to our system of comparison, PHAT is a better buy in the short-term than ADXN.

Price Growth

ADXN (@Biotechnology) experienced а -3.19% price change this week, while PHAT (@Biotechnology) price change was -5.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.10%. For the same industry, the average monthly price growth was -18.18%, and the average quarterly price growth was -15.20%.

Reported Earning Dates

ADXN is expected to report earnings on Dec 03, 2026.

PHAT is expected to report earnings on Oct 29, 2026.

Industries' Descriptions

@Biotechnology (-1.10% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
ADXN
Daily Signal:
Gain/Loss:
PHAT
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

ADXN and

Correlation & Price change

A.I.dvisor indicates that over the last year, ADXN has been loosely correlated with ANVS. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if ADXN jumps, then ANVS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ADXN
1D Price
Change %
ADXN100%
+2.64%
ANVS - ADXN
43%
Loosely correlated
-0.15%
CVM - ADXN
39%
Loosely correlated
-0.62%
PHAT - ADXN
28%
Poorly correlated
-0.28%
INTS - ADXN
27%
Poorly correlated
+1.27%
RIGL - ADXN
26%
Poorly correlated
-0.04%
More

PHAT and

Correlation & Price change

A.I.dvisor indicates that over the last year, PHAT has been loosely correlated with ALNY. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if PHAT jumps, then ALNY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PHAT
1D Price
Change %
PHAT100%
-0.28%
ALNY - PHAT
45%
Loosely correlated
+0.97%
QCLS - PHAT
39%
Loosely correlated
+3.50%
ATRA - PHAT
36%
Loosely correlated
+0.86%
KURA - PHAT
32%
Poorly correlated
-0.20%
STOK - PHAT
32%
Poorly correlated
+0.08%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
WDFC210.1817.62
+9.15%
WD-40 Company
CSL352.6012.50
+3.68%
Carlisle Companies
MYGN5.760.19
+3.41%
Myriad Genetics
AEMD5.190.12
+2.37%
Aethlon Medical Inc
TNYA0.39N/A
-0.56%
Tenaya Therapeutics